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Background: Turner syndrome (TS) is the most common chromosomal abnormality in females and is associated
with several co-morbidities. It commonly results from X monosomy which is diagnosed on a 30 cell karyotype.
Congenital heart disease is a clinical feature in 30% of cases. It is becoming evident that TS patients have an
increased risk of cardiovascular and cerebrovascular diseases.
Scope of review: This review provides a detailed overview of the literature surrounding cardiometabolic health in
childhood and adolescent TS. In addition, the review also summarises the current data on the impact of growth
hormone (GH) therapy on cardiometabolic risk in paediatric TS patients.
Major conclusions: Current epidemiological evidence suggests that young women and girls with TS have
unfavourable cardiometabolic risk factors which predispose them to adverse cardiac and cerebrovascular
outcomes in young adulthood. It remains unclear whether this risk is the result of unidentiﬁed factors which
are intrinsic to TS, or whether modiﬁable risk factors (obesity, hypertension, hyperglycaemia) are contributing
to this risk.
General signiﬁcance: From a clinical perspective, this review highlights the importance of regular screening and
pro-active management of cardiometabolic risk from childhood in TS cohorts and that future research should
aim to address whether modiﬁcation of these variables at a young age can alter the disease process and athero-
sclerotic outcomes in adulthood.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Turner syndrome (TS) is themost common chromosomal abnormal-
ity in females, affecting 3% of all female foetuses [1] and occurring in
1:2500 live female births. It results from complete or partial X chromo-
some monosomy and is associated with a characteristic phenotype and
comorbidities. Diagnosis requires the study of aminimum30 cell karyo-
type [2]. Congenital cardiovascular disease affects 30% of patients with
TS [3] however, it is becoming increasingly recognised that TS patients
are at an increased risk of early acquired cardiovascular and cerebrovas-
cular diseases and have a 2-fold risk of developing coronary artery
disease [2,4].
An established precursor to cardiovascular disease is atherosclerosis,
which results from amultifactorial process through a combination of sev-
eral modiﬁable (hypertension, hyperglycaemia, hyperlipidaemia and
obesity) and non-modiﬁable (including age, gender and family history)
risk factors. The process of atherosclerosis begins in early childhood and
metabolic risk factors at age 9 years in healthy children can be predictive
of subclinical atherosclerosis in adulthood [5]. The early stages of athero-
sclerosis are reversible and thus, early detection offers a theoretical win-
dow of opportunity to modify disease progression. Similarly, in TS, the
atherosclerotic process starts early [6] and the epidemiological data sug-
gests that there is an associated 3-fold risk of mortality from cardiovascu-
lar and cerebrovascular diseases [7,8]. This review will discuss current
data on cardiometabolic risk factors and acquired cardiovascular diseases
in young girls with TS.2. Cardiometabolic risk factors in Turner syndrome in childhood
2.1. Glucose metabolism
Approximately 35% of young girls with TS have abnormalities in car-
bohydrate metabolism and the frequency of impaired glucose metabo-
lism varies with karyotype: mosaic TS patients have normal glucose
tolerance compared to monosomy X patients [9]. Furthermore, type 2
diabetes mellitus (T2DM) is up to 4 times more common in TS patients
[1] and the frequency of T2DM can vary according to karyotype: 43% in
isochromosomeXq as comparedwith 9% in del Xq [9]. This suggests that
haploinsufﬁciency of genes on Xp increases the impaired glucose me-
tabolism and risk of T2DMand possibly impacts transcription factors in-
volved in pancreatic islet and beta cell function [10].
The pathophysiology of impaired glucose tolerance in TS still re-
mains unclear but there are several studies which attempt to elucidate
the nature of the impairment. Adult women with TS have higher 2 h
glucose levels and reduced measures of insulin secretion (HOMA-b
and ﬁrst phase insulin release) when compared to age matched
controls, suggesting impaired insulin secretion [11]. However, studies
demonstrating discrete reduction in insulin secretion following a glu-
cose load in an IVGTT suggest a dysfunction in insulin secretion [12].
There is a study demonstrating higher fasting glucose and insulin levels
(HOMA-S) using hyperinsulinemic–euglycemic clamps in 16 TS sub-
jects, when compared to age- and body composition-matched controls,
suggestive of decreased insulin sensitivity and lower whole body insu-
lin sensitivity [13].
In paediatric TS cohorts, 34% of TS patients have impaired glucose
tolerance on oral glucose tolerance testing (OGTT) as compared to 8%
of controls but insulin sensitivity improves as the girls progress to 12–
16 years of age [9]. Similar ﬁndings have been demonstrated inadolescents by using the IVGTT [14]. However, the reverse has also
been demonstrated using the euglycaemic insulin clamp technique,
where TS girls and adolescents have a signiﬁcant reduction in insulin
sensitivity and in non-oxidative glucose disposal compared to age-
matched controls [15]. In a recent paediatric cross-sectional study eval-
uating cardiometabolic, 5/19 girls with TS and 0/17 controls had signif-
icantly impaired fasting glucose or impaired glucose tolerance on OGTT,
and ISSI-2 (insulin secretion sensitivity index-2)was signiﬁcantly lower
in TS, suggesting a pancreatic beta cell dysfunction [16].
What is evident from these studies is that girls and women with TS
are at increased risk of impaired glucose metabolism and T2DM and
that the aetiology, though inconclusive, is multifactorial. Further, in TS,
it appears that the processes of insulin secretion and sensitivity are dy-
namic at different ages of childhood, adolescence and adulthood. This
maybe the result of small study numbers and varying age range as
well as varied insulin methodologies used. Larger studies are clearly re-
quired and especially studies examining glucosemetabolism in paediat-
ric TS cohorts and its impact on cardiovascular risk in adulthood.
2.2. Body composition
Patients with TS have an altered body composition when compared
to age-matched controls. This may be due to the fact that TS cohorts are
on average 20 cm shorter but often have similar weights compared to
controls resulting in an unfavourable body composition, with increased
bodymass index (BMI) andwaist circumference [17–21]. However, it is
evident from research methodologies, such as dual energy X-ray scan
(DXA) and magnetic resonance scanning (MRI) that it is not just the
shorter average height which places TS cohorts in an unfavourable
body composition. DXA and MRI have demonstrated that adult TS co-
horts have higher fat mass (FM) and lower lean body mass (LBM)
with alterations in regional fat distribution (increased visceral FM, de-
creased truncal LBM and decreased skeletal muscle mass) [22,23]. A
concerning ﬁnding is that the paediatric data demonstrates similar
trends. TS girls have higher waist circumference than age-matched
and BMI-SDS-matched control [16] and given that visceral fat is meta-
bolically active and contributes to the development of insulin resistance,
T2DM and metabolic syndrome, this presents clinicians with an oppor-
tunity for early detection and intervention in TS girls.
2.3. Lipid abnormalities
There are data which suggest that lipid metabolism in TS cohorts is
altered, with approximately 50% of TS patients over 21 years displaying
hypercholesterolemia [24]. Total cholesterol and low density lipoprotein
cholesterol (LDLc) are elevated in TS and a positive correlation exists be-
tween total cholesterol and LDLc levels and age [24,25,26]. Furthermore,
low high density lipoprotein cholesterol (HDLc) levels occur in about
25% of adult TS women [1] and other studies show increased triglycer-
ides in TS women [27]. These are all components of the metabolic
syndrome.
In paediatric TS cohorts, higher total cholesterol, triglycerides and
HDL cholesterol have been described [6,28,29]. Furthermore, there is a
signiﬁcant positive correlation between LDLc and carotid intima
media (cIMT) thickness and a negative correlation between HDLc
(r = 0.518, p b 0.01) and cIMT [6] suggesting that dyslipidaemia may
be associated with atherosclerosis in children with TS. Ross et al.
(1995) [52] has previously shown a positive correlation between
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have suggested that this may be related to primary ovarian failure.
The exact cause for dyslipidaemia is unclear but theories exist such
as foetal programming; where a negative correlation between birth
weight and total cholesterol and triglycerides in TS has been demon-
strated [30]. Gene dosagemay also be important;where 45,XOmonoso-
my displays signiﬁcantly higher levels of triglycerides and LDLc as well
as aberrations in LDLc and HDLc particle size, density and concentration
[8]. Lipid particle size may also play a role, with smaller particle size in
TS patients compared with karyotypically-matched controls [25].
In summary, the data suggest that dyslipidemia is prevalent in TS pa-
tients from childhood and that it may be dynamicwith age and puberty.
However, though the theories attempting to explain dyslipidaemia in TS
are inconclusive, what is an emerging concern is that dyslipidaemia is
evident in childhood and given that it is an established risk factor for ac-
quired cardiovascular morbidity and mortality in adulthood. This is an
area which requires constant clinical monitoring, as recommended by
the current TS guidelines [1] as well as further research.
2.4. Hypertension
Girls with TS have an increased risk of hypertension in childhood
and in adulthood, even after excluding TS patients with cardiac or
renal defects. Approximately 50% of adults with TS have clinical hyper-
tension [31]. Approximately, 1 in 4 young girls and 1 in 2 adult women
with TS require anti-hypertensive treatment [4,32]. Thirty percent of
girlswith TS aremildly hypertensive on 24h ambulatory blood pressure
monitor (ABPM) and 50% have abnormal diurnal blood pressure (BP)
regulation [33,34] with elevations in diastolic and systolic night/day ra-
tios. This ﬁnding has been replicated in TS adult subjects [33]. These
ﬁndings suggest that clinically detectable hypertension is preceded by
a phase of dysregulation of normal BPwhich is detectable on ambulato-
ry blood pressure monitoring.
Paediatric studies quote a wide range of prevalence of hypertension,
from 7% [2] up to 40% [35,2]. TS girls demonstrate higher systolic, dia-
stolic and mean BP and resting heart rate [18] with a loss of the normal
circadian rhythm of diastolic BP [36]. In one recent study of TS subjects
aged 7–23 years, ambulatory blood pressure monitoring identiﬁed hy-
pertension in 5/23 subjects, and 12/23 lacked the normal nocturnal
dip in blood pressure. In the same study, conventional BP monitoring
identiﬁed hypertension in only 1/5 patients [35]. These data suggest
that 24 h ambulatory blood pressure monitoring might identify early
hypertension, i.e. loss of the nocturnal dip in BP. Currently, however,
ABPM is not considered a routine ﬁrst line investigation for hyperten-
sion in individuals with TS who do not have underlying cardiovascular
disease but there may be an argument to change this and begin to use
ambulatory BP monitoring earlier in TS.
Hypertension is a well-established risk factor for atherosclerosis and
hypertension confers a risk of end-organ damage in non-TS subjects.
This applies to TS subjects also [33]. In TS, there is a negative correlation
betweendipping of the nocturnal diastolic bloodpressure (DBP) and ca-
rotid intima media thickness (cIMT) (r =−0.641, p = 0.000) [36,33].
Thus, loss of the normal nocturnal dip in DBP is associated with in-
creased arterial stiffness in children. Increased cIMT is a precursor of
atherosclerotic plaque advancement and cardiovascular risk. Further-
more, endothelial dysfunction, an indicator of early atherosclerosis,
has been demonstrated in BMI-matched TS paediatric cohorts (up to
8 years of age) using peripheral arterial tonometry (PAT) [29].
These data are confounded in TS subjects. For example, hypertension
in TS correlateswith increasing BMI [37] and BPmeasurements in TS are
complicated by shorter height; so corrections for BMI, height and/or
body surface area (BSA) have been suggested and should be considered
[38].
In summary, hypertension is prevalent in TS subjects from child-
hood. It is associated with several poor cardiovascular outcomes in
adulthood and can be detected in its earliest form as loss of nocturnaldiastolic BP dip on ambulatory blood pressure monitoring. Hyperten-
sion in TS subjects begins in childhood and may be complicated by co-
existing congenital heart or renal disease. However, it is detectable in
its early stages. Hypertension is an important modiﬁable risk factor for
aortic dissection [40], ischaemic heart disease and cerebrovascular
disease. These data provides compelling evidence for early detection,
regular monitoring and aggressive treatment of hypertension in girls
with TS and perhaps consideration should be given to the use of ambu-
latory blood pressure monitoring early in the monitoring phase.
2.5. Metabolic syndrome
Metabolic syndrome (MetS) comprises a cluster of cardiovascular
risk factors including hypertension, abdominal obesity, and impaired
glucose metabolism, which confer an adverse cardiovascular outcome
in adulthood. Though there is a lack of consistent diagnostic criteria
for MetS there are a few proposed deﬁnitions [39]. Girls and adolescent
women with TS also have adverse cardiometabolic proﬁles, placing
them at increased risk of cardiovascular and cerebrovascular diseases.
Interestingly, however, there are limited data on the prevalence of
MetS in TS. A recent study [20] in an adult TS cohort of 85 patients re-
ported a prevalence of 4.7% of MetS, using the International Diabetes
Federation deﬁnition. Those with MetS included 12.5% obese and 4.3%
non-obese. Data in paediatric TS cohorts are limited, but a recent
study showed that 7/19 paediatric TS subjects met one criterion for
MetS, 8/19 met two criteria however, and 0/19 were diagnosed with
MetS [16]. Given that the data in the paediatric TS cohort are limited
and knowing that the risk factors for MetS are prevalent in young girls
with TS, future researchmust address questions about the impact of car-
diometabolic risk factors in paediatric TS on adult cardiovascular out-
come Refer to Figs. 1 and 2 for a detailed schematic of the interaction
of the various cardiometabolic risk factors in Turner Syndrome.
3. Growth hormone treatment and cardiometabolic risk in
Turner syndrome
Growth hormone (GH) is the primary growth-promoting treatment
for short stature in TS. GH also has an impact on metabolic processes.
Thus it is relevant to ascertain potential beneﬁcial or adverse effects of
GH therapy on metabolic risk factors in girls with TS.
3.1. The impact of GH treatment on glucose metabolism in TS
The effect of GH on glucose metabolism in TS has been extensively
studied but the results are conﬂicting. Earlier randomised, placebo-
controlled cross-over studies demonstrated that 2 months of GH treat-
ment is associated with worsening insulin sensitivity, measured by
HOMA-IR and composite insulin sensitivity index [40]. Conversely,
studies of long-term treatment (4 years) with GH doses up to 8 IU/
m2/day suggest that GH does not affect fasting glucose levels, but that
it does increase fasting and post-prandial insulin levels however, these
ﬁndings normalise within 6 months of discontinuing GH, suggesting a
picture of transient insulin resistance [41–43]. In another study, GH
treatment was associated with reduced insulin sensitivity by the
QUICK-Imethod, butwithout an impaired response to an oral glycaemic
load. Reassuringly, the reduced insulin sensitivity normalised within
12 months of cessation of GH treatment, again supporting the hypothe-
sis of transient insulin resistance [43]. The decreased insulin sensitivity
associated with GH therapy may vary with age, with less effects in TS
subjects older than 12 years [44]. Additionally, increased BMI, which
commonly exists in TS, may have a negative impact on insulin sensitiv-
ity [44]. Finally, it may be that the impact of GH on glucose metabolism
may improve following cessation of the treatment [44]. Although the
pathophysiology of impaired glucose sensitivity effects of GH in TS is
unclear, the dysregulation appears to be reassuringly transient.
GLUCOSE METABOLISM
Impaired glucose tolerance
Pancreatic beta cell dysfunction
Reduced Insulin sensitivity
BODY COMPOSITION
Increased Body Mass Index
Increased Fat Mass    
Reduced lean body Mass
Increased Waist Circumference        
Increased cardiovascular morbidity and mortality
Increased risk of acute aortic dissection
Increased stroke incidence from 2nd decade of life
Increased risk of ischaemic heart disease from 5th decade of life 
LIPID Abnormalities
Hypercholesterolemia
Increased LDL
Increased TG
Increased Total 
Cholesterol
Dyslipidaemia dynamic 
with age and puberty
Correlation with cIMT
HYPERTENSION
40% Abnormal 
ABPM
50% Abnormal 
diurnal BP regulation
Fig. 1. Cardiometabolic and vascular risks in girls and adolescents with Turner syndrome.
BLOOD PRESSURE
HYPERTENSION
GLUCOSE 
METABOLISM
REDUCED 
INSULIN 
SENSITIVITY
TYPE2 
DIABETES
ANTHROPOMETRICS
REDUCED LEAN 
BODY MASS
INCREASED FAT 
MASS, BMI,
WAIST 
CIRCUMFERENCE
LIPID ABNORMALITIES
INCREASED LDL, TG, TOTAL 
CHOL
GH AXIS
RELATIVE GH
RESISTANCE
PRIMARY OVARIAN FAILURE
INCREASED LH, FSH
DEVELOPMENT AND PROGRESSION OF 
ATHEROSCLEROSIS
AORTIC DILATION
AORTIC DISSECTION
ISCHAEMIC HEART DISEASE
CEREBROVASCULAR EVENTS
ADVERSE EFFECT ON CAROTID INTIMAL 
MEDIA THICKNESS
Fig. 2. Interaction of cardiovascular and metabolic risk factors in Turner syndrome.
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The beneﬁcial effect of GH on body composition has been demon-
strated in cohorts other than TS [45]. GH has a positive impact on
body composition in GH-treated TS cohorts: it leads to reduced total
body fat, subcutaneous body fat and intra-abdominal fat, as quantiﬁed
on DXA scan after 2 months of GH therapy [46,40], increased lean
body mass and reduced fat mass [47].
GH therapy also positively inﬂuences the metabolic proﬁle by de-
creasing total cholesterol and reducing LDLc, while increasing HDLc
and triglycerides [27]. However, these changes are evident in the ﬁrst
4 years of GH therapy and might not be sustained on discontinuing
treatment [27]. A similar observation has been demonstrated in paedi-
atric TS cohorts [48]. Again, it would seem that GH has the potential
for positive impact on body composition and lipid metabolism, but it
is difﬁcult to establish this with certainty in the absence of large longitu-
dinal studies.
3.3. The impact of GH treatment on blood pressure
The studies examining the impact of GH on blood pressure control
showconﬂictingdata. In one study, diastolic BPwas reduced signiﬁcant-
ly in a cohort of 39 GH-treated TS patients, and this BP reduction was
sustained up to 5 years after discontinuing treatment [49]. However,
when TS girls are treated with GH for up to 7 years with doses of 8 IU/
m2/day, there does not appear to be a beneﬁcial effect on blood pressure
[50]. Further research is required to address these disparate results.
4. Conclusion
Current epidemiological evidence suggests that young women and
girls with TS have unfavourable cardiometabolic risk factors which
predispose them to adverse cardiac and cerebrovascular outcomes in
young adulthood. The literature also describes adverse cardiovascular
risk factors which place them at risk of developing the early stages of
atherosclerosis, even in the paediatric age group. But what remains
unclear is whether there are unidentiﬁed factors intrinsic to TS, which
are also contributory to the cardiovascular risk or whether this is due
to the adverse but modiﬁable risk factors (obesity, hyperglycaemia,
hypertension and hyperlipidaemia) which are identiﬁed in childhood.
The importance of regular screening and pro-active management of
cardiometabolic risk from childhood in TS cohorts is clear. Future
research should address whether modiﬁcation of these variables at a
young age can alter the disease process and atherosclerotic outcomes
in adulthood, as well as to determine the potential risks and beneﬁts of
initiating speciﬁc therapies for factors such as obesity, hyperglycaemia,
hypertension and hyperlipidaemia, at younger ages. Finally, from a clin-
ical perspective, the foundation of delivering best practice care to girls
and women with TS should include physician awareness of the cardio-
metabolic and vascular risks in TS.
Suggested screening of cardiometabolic risk factors in young girls
and adult women with TS [51]
Adapted from Bondy (2007).•Annual blood pressure assessment
–manual syphgmomanometer can be used
–ABPM can be considered if clinically indicated
•Annual check of fasting blood glucose level
•Annual assessment of fasting lipids in older girls and adultsTransparency documents
The Transparency documents associated with this article can be
found, in the online version.References
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